Related Experiment Videos
[Prognostic significance of CD7 expression in adult acute myeloid leukemia]
Insights
CD7 expression is not a significant prognostic factor in de novo acute myeloid leukemia (AML). This study found no difference in complete remission, disease-free survival, or overall survival between CD7-positive and CD7-negative AML patients.
Area of Science:
- Hematology
- Immunophenotyping
- Oncology
Context:
- Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy.
- Prognostic markers are crucial for guiding AML treatment strategies.
- CD7 is a surface marker expressed on various hematopoietic cells.
Purpose:
- To investigate the prognostic significance of CD7 expression in de novo acute myeloid leukemia (AML).
Summary:
- This study analyzed 52 de novo AML patients, classifying them based on French-American-British morphology and CD7 expression.
- Complete remission (CR), disease-free survival (DFS), and overall survival (OS) were evaluated.
- No significant differences in CR, DFS, or OS were observed between CD7-positive AML and CD7-negative AML patients.
Impact:
- CD7 expression is unlikely to be a reliable prognostic factor in de novo AML.
- Findings may influence risk stratification and treatment decisions for AML patients.
- Further research may explore other immunophenotypic markers for AML prognostication.
Abstract:
To evaluate the prognostic significance of CD7 expression in de novo acute myeloid leukemia (AML), we studied 63 patients with AML who had been admitted to our hospital between September 1989 and January 1996. Even of the patients were later eliminated from the study (9 due to insufficient surface marker analyses, and 2 due to early death). The remaining 52 patients (median age: 42.5 years) were evaluated for morphologic subtype, immunophenotypic classification, complete remission (CR), disease-free survival (DFS) and overall survival (OS). All 52 patients were grouped by the French-American-British classification system: 10 as M1, 16 as M2, 11 as M3, 8 as M4, 5 as M5, and 2 as M6. Ten of the patients expressed CD7 on their leukemia cells (positive rate > or = 25) and were classified as CD7(+)AML, with morphological subtypes as follows: 3 as M1, 6 as M2, and 1 as M3. Thirty-three of the 42 patients with CD7 + AML (78.6%) and 6 of the 10 patients with CD7 + AML (40%) achieved CR. DFS and OS rates for the patients with CD7(+)AML were 22.1% and 35.4%, respectively; those for the CD7(+)AML patients were 53.3% and 44.4%, respectively. No significant differences in gender hematological findings, clinical manifestations such as hepatosplenomegaly, lymphadenopathy, or incidence of central nervous system involvement, CR rate, and DFS distinguished patients with CD7(+)AML from those with CD7(+)AML. These suggest that CD7 expression is unlikely to be a prognostic factor in AML.